The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 355:1822-1824 October 26, 2006 Number 17
NextNext

A Pause, Progress, and Reassessment in Lung Cancer Screening
Michael Unger, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by The International Early Lung Cancer Action Program Investigators
-PubMed Citation
We are all well acquainted with the frightfully high incidence of lung cancer and the short survival of patients after the diagnosis has been made. The extremely low survival rate is attributable in part to the advanced stage of the disease at the time of diagnosis. The 5-year survival rate among patients with stage I lung cancer is approximately 70%, and it declines to about 5% among patients with stage IV lung cancer. The serendipitous discovery of lung cancer in asymptomatic people is currently the principal way in which stage I lung cancer is detected.

Unfortunately, we have not left . . . [Full Text of this Article]


Source Information

From the Pulmonary Cancer Detection and Prevention Program, Fox Chase Cancer Center, Philadelphia.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.